The global pharmaceutical chemicals market is estimated to be valued at USD 137.76 Bn in 2024 and is expected to reach USD 224.32 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.
To learn more about this report, request sample copy
The market has been witnessing steady growth on account of increasing investments in R&D by major players and the growing generics market worldwide. Regulatory approvals and drug development have also accelerated. The demand for pharmaceutical chemicals is expected to be primarily driven by growth in the generics market globally over the coming years. Increasing prevalence of diseases globally is also supporting the need for development of new drug molecules. Further, the market is witnessing consolidation with major players undertaking mergers and acquisitions to expand their product pipelines. Innovation and development of specialty chemicals will present new growth opportunities in the market.
Rising healthcare needs of aging global population
As life expectancy increases and populations age around the world, the demand for pharmaceutical products and healthcare services is growing substantially. People are living longer with chronic diseases like diabetes, cancer, heart disease, and others which require long term medical treatment and management. According to the United Nations, the number of people aged 60 years and older is expected to more than double by 2050 and reach around 2 billion people globally. The aging population needs access to innovative drugs and therapies to improve quality of life and cope with health challenges. Pharmaceutical manufacturers are racing to develop specialized drugs targeting the healthcare needs of elderly patients. Many nations are also expanding healthcare coverage and access to medications for senior citizens. This widening segment of aging consumers presents a massive market opportunity for the pharmaceutical chemicals industry to supply active pharmaceutical ingredients and develop specialized medicines. The industry must prepare for steady long-term growth driven by the healthcare demands of a rapidly expanding global population of older individuals.
Another important driver is the increasing rate of non-communicable diseases like cancer, diabetes, and cardiovascular diseases in developing nations. As emerging market economies progress and lifestyles become more sedentary, risk factors for these chronic illnesses are growing sharply. Countries that had previously only grappled with infectious diseases and undernutrition are now facing a dual burden of communicable and non-communicable diseases. Lack of access to primary healthcare and medical services compounds the problem in many developing regions. Multinational pharmaceutical companies and local drug makers have a significant chance to fill this treatment gap and expand accessibility of drugs combating cancer, diabetes, heart diseases and other common chronic conditions. The continuous economic growth and urbanization witnessed across Asia, Africa, Latin America, and other emerging markets is translating to a fast-rising patient base requiring long term medical care. Catering to this burgeoning patient pool of non-communicable diseases will be instrumental in sustaining high growth levels for the global pharmaceutical chemicals market in the coming decades.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients